Avacta Group Plc (AVCT.L)

45.30 +0.80 (+1.80%) At close: 05:06PM BST

Avacta Group Plc

Thorp Arch Estate
Unit 20 Ash Way
Wetherby LS23 7FA
United Kingdom
44 1904 217 070
https://www.avacta.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 120

Key executives

Name	Title	Pay	Exercised	Year born
Dr. David Alastair Maclaughlin Smith	CEO & Executive Director	444k	N/A	1966
Mr. Tony Gardiner	CFO, Company Secretary & Executive Director	273k	N/A	1971
Dr. Christina Marie Coughlin B.S., M.D., Ph.D.	Head of Research & Development, Interim Chief Medical Officer and Director	37k	N/A	1970
Ms. Emma Wright	Group In-House Counsel	N/A	N/A	N/A
Mr. Michael Vinegrad	Group Communications Director	N/A	N/A	N/A
Mr. R. Craig Slater FCA	Chief Operating Officer of Diagnostics	69k	N/A	1964
Dr. Matt Johnson	Chief Scientific Officer of Diagnostics	N/A	N/A	N/A
Dr. Fiona McLaughlin FSB, Ph.D.	Chief Scientific Officer of Therapeutics Division	N/A	N/A	1970
Mr. David Wilson	Chief Commercial Officer of Diagnostics	N/A	N/A	N/A
Ms. Karen Harrison	Chief Operating Officer of Therapeutics Division	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Corporate governance

Avacta Group Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.